Dr. Degnim's clinical interests are related to breast cancer surgery and other rare tumor types such as angiosarcoma, as well as high risk breast lesions. Dr. Degnim also leads many research projects related to predicting individual breast cancer risk, and using novel approaches to prevent breast cancer, including topical agents and vaccines. She leads the Mayo Clinic Benign Breast Disease Cohort, a multidisciplinary research study involving approximately 15,000 women, including the study of histology, immunology, genomics, and mammographic changes that are associated with risk of developing breast cancer.